ArticleACS omega2018
Top-Down Fabricated Silicon Nanowire Arrays for Field-Effect Detection of Prostate-Specific Antigen.
Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 40 citations in OpenAlex.
- On the Use of Ag/AgCl Reference Electrode in Silicon Nanowire Field Effect Transistors for pH and Biosensing Applications.Sensors (Basel, Switzerland) · 2026Review
- Advanced Materials for Biological Field-Effect Transistors (Bio-FETs) in Precision Healthcare and Biosensing.Advanced healthcare materials · 2025Review
- Ultrasensitive Detection of PSA Using Antibodies in Crowding Polyelectrolyte Multilayers on a Silicon Nanowire Field-Effect Transistor.Polymers · 2024Article
- Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer.Sensors (Basel, Switzerland) · 2023Article
- Aptamer-functionalized field-effect transistor biosensors for disease diagnosis and environmental monitoring.Exploration (Beijing, China) · 2023Review
- Aptamers as Theragnostic Tools in Prostate Cancer.Biomolecules · 2022Review
- Field-Effect Capacitors Decorated with Ligand-Stabilized Gold Nanoparticles: Modeling and Experiments.Biosensors · 2022Article
- Process Variability in Top-Down Fabrication of Silicon Nanowire-Based Biosensor Arrays.Sensors (Basel, Switzerland) · 2021Review
- Point-of-care-ready nanoscale ISFET arrays for sub-picomolar detection of cytokines in cell cultures.Analytical and bioanalytical chemistry · 2020Article
- A review on nanomaterial-based field effect transistor technology for biomarker detection.Mikrochimica acta · 2019Review
- The influence of geometry and other fundamental challenges for bio-sensing with field effect transistors.Biophysical reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly sensitive electrical detection of biomarkers for the early stage screening of cancer is desired for future, ultrafast diagnostic platforms. In the case of prostate cancer (PCa), the prostate-specific antigen (PSA) is of prime interest and its detection in combination with other PCa-relevant biomarkers in a multiplex approach is advised. Toward this goal, we demonstrate the label-free, potentiometric detection of PSA with silicon nanowire ion-sensitive field-effect transistor (Si NW-ISFET) arrays. To realize the field-effect detection, we utilized the DNA aptamer-receptors specific for PSA, which were covalently and site-specifically immobilized on Si NW-ISFETs. The platform was used for quantitative detection of PSA and the change in threshold voltage of the Si NW-ISEFTs was correlated with the concentration of PSA. Concentration-dependent measurements were done in a wide range of 1 pg/mL to 1 μg/mL, which covers the clinical range of interest. To confirm the PSA-DNA aptamer binding on the Si NW surfaces, a sandwich-immunoassay based on chemiluminescence was implemented. The electrical approach using the Si NW-ISFET platform shows a lower limit of detection and a wide dynamic range of the assay. In future, our platform should be utilized to detect multiple biomarkers in one assay to obtain more reliable information about cancer-related diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.